Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232349 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Galantamine to Treat Schizophrenia
A Phase 4 study, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Terminated
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT00232349 is a Phase 4 study that was terminated before completion, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 21 participants.
The verdict
NCT00232349, a Phase 4 study, was terminated before completion, sponsored by Seattle Institute for Biomedical and Clinical Research.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements from baseline to end of study on a measure of quality of life and a measure of independent living skills.
Interventions
- DRUG galantamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232349
The ClinicalTrials.gov registry entry for NCT00232349 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which galantamine is the first listed.
NCT00232349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232349 about?
NCT00232349 is a clinical study titled "Efficacy of Galantamine to Treat Schizophrenia". The purpose of this study was to determine if treatment with adjunctive galantamine is effective in the reduction of functional impairments in patients with schizophrenia and schizoaffective disorder. It was hypothesized that adjunctive galantamine would yield clinically significant improvements fro...
What is the current status of trial NCT00232349?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2005-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00232349?
The interventions under investigation include: galantamine (DRUG).
Who is sponsoring clinical trial NCT00232349?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.